Results 211 to 220 of about 73,292 (239)

Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol

Psychopharmacology, 1992
We developed a sensitive HPLC assay to measure haloperidol (HA) and its metabolite, reduced haloperidol (RH), in plasma and whole blood. The conditions under which HA might be converted to RH during collection and analysis of blood were examined. Provided the blood was kept at 0 degrees C, erythrocyte ketone reductase activity was insignificant.
Eyles, Darryl W., Whiteford, Harvey A., Stedman, Terry J., Pond, Susan M.   +3 more
openaire   +4 more sources

Pharmacokinetics of Haloperidol

Clinical Pharmacokinetics, 1989
Haloperidol has been used extensively for the treatment of psychotic disorders, and it has been suggested that the monitoring of plasma haloperidol concentration is clinically useful. Different assay methodologies have been used in research and clinical practice to examine the relationship between response and plasma concentration of the drug. Chemical
J. S. Froemming, C. M. Davis, Michael W. Jann, Y. W. F. Lam, Y. W. F. Lam, Y. W. F. Lam   +5 more
openaire   +3 more sources

Haloperidol Analgesia

Southern Medical Journal, 1981
Haloperidol was observed to be an effective analgesic, alone and in combination with opiates, in a patient with severe radiation fibrosis and necrosis. Previously, high doses of methadone and morphine, along with amitriptyline, had caused dangerous sedative side effects without providing adequate pain relief.
J L, Daw, S A, Cohen-Cole
openaire   +2 more sources

Intersubject Variation in the Pharmacokinetics of Haloperidol and Reduced Haloperidol

Journal of Clinical Psychopharmacology, 1989
Single oral doses (5 mg) of haloperidol were administered to 36 healthy men (26 black, 10 white) of whom 28 (22 black, 6 white) completed the study. Plasma samples harvested over 96 hours were analyzed for haloperidol and reduced haloperidol by means of a new high performance liquid chromatographic method.
Kamal K. Midha, Derek A. Ganes, E. D. Korchinski, B.S. Chakraborty, John W. Hubbard, Edward M. Hawes, Gordon McKay, David L. Keegan   +7 more
openaire   +2 more sources

Interconversion between haloperidol and reduced haloperidol in healthy volunteers

European Journal of Clinical Pharmacology, 1989
The interconversion between haloperidol (HAL) and reduced haloperidol (RHAL) was examined following their separate administration in low (5 mg) single oral doses to 15 young healthy male volunteers in a crossover design. Using an ultrasensitive HPLC method plasma concentrations of HAL and RHAL were monitored over a period of one week following each ...
Gordon McKay, J.K. Cooper, E. D. Korchinski, John W. Hubbard, T. Gurnsey, Edward M. Hawes, Kamal K. Midha, B.S. Chakraborty   +7 more
openaire   +3 more sources

The Measurement of Haloperidol and Reduced Haloperidol in Neonatal Hair as an Index of Placental Transfer of Maternal Haloperidol

Therapeutic Drug Monitoring, 1991
Hair samples were collected at time of delivery from three neonates and their schizophrenic mothers, who had been taking haloperidol (HP) during the perinatal period to control worsening psychotic symptoms. Maternal hair was cut into 1-cm lengths, and concentrations of HP and its major metabolite, reduced haloperidol (RHP), were measured by high ...
Ken-ichi Yamada, Hiroyuki Matsuno, Toshihiko Uematsu, Mitsuyoshi Nakashima   +3 more
openaire   +3 more sources

Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996
1. Haloperidol and reduced haloperidol plasma levels were measured in schizophrenic patients who received both oral (10 mg, N=16 and 20 mg, N=4) and depot haloperidol treatment 2. Patients were of Asian ethnicity and were safely and effectively converted from oral to depot therapy using a loading dose regimen using a 100 mg weekly injection interval ...
F C Wei, Wen Ho Chang, C Piao-Chien, Michael W. Jann, Hsin-Nan Lin   +4 more
openaire   +2 more sources

Parkinsonism by haloperidol and piribedil

Psychopharmacology, 1978
Three groups of schizophrenic patients were treated with haloperidol, with a low dose of piribedil (a dopamine agonist), and with a combination of the two treatments, respectively. After a few days, all 7 patients treated with the drug combination showed marked rigidity and akinesia, while patients treated with haloperidol alone (4) and piribedil alone
CORSINI, GIOVANNI UMBERTO, DELZOMPO M, SPISSU A, MANGONI A, GESSA GL   +4 more
openaire   +4 more sources

Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol

European Neuropsychopharmacology, 1994
Plasma haloperidol (HL) and reduced haloperidol (RH) levels were measured in 60 schizophrenic patients treated with high to very high HL doses of 40-200 mg/day. Plasma samples were obtained at steady-state conditions and 10-12 h after the evening dose and prior to the morning dose. RH/HL ratios were shown to be dose-dependent.
Yann Shou Shieh, Hui Ching Liu, Michael W. Jann, Wen Ho Chang, Ching Piao Chien   +4 more
openaire   +3 more sources

Variability in Declining Haloperidol and Reduced Haloperidol Plasma Concentrations upon Haloperidol Cessation

Drug Investigation, 1993
Plasma concentrations of haloperidol and its reduced metabolite were measured in 6 schizophrenic patients after discontinuation of oral haloperidol treatment. Patients were on haloperidol 10mg twice daily for at least 2 to 4 weeks prior to cessation of treatment to ensure haloperidol steady-state concentrations had been achieved.
Wen Ho Chang, Shih Ku Lin, Y. W. Francis Lam, Michael W. Jann   +3 more
openaire   +2 more sources